
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About
Solventum Corp. (SOLV)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: SOLV (3-star) is a STRONG-BUY. BUY since 28 days. Profits (-0.41%). Updated daily EoD!
Year Target Price $82.17
Year Target Price $82.17
1 | Strong Buy |
2 | Buy |
8 | Hold |
0 | Under performing |
1 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 16.11% | Avg. Invested days 47 | Today’s Advisory Strong Buy |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 13.06B USD | Price to earnings Ratio 34.77 | 1Y Target Price 82.17 |
Price to earnings Ratio 34.77 | 1Y Target Price 82.17 | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 47.16 - 85.92 | Updated Date 06/29/2025 |
52 Weeks Range 47.16 - 85.92 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.17 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 4.56% | Operating Margin (TTM) 7.73% |
Management Effectiveness
Return on Assets (TTM) 3.72% | Return on Equity (TTM) 10.66% |
Valuation
Trailing PE 34.77 | Forward PE 13.61 | Enterprise Value 20434555094 | Price to Sales(TTM) 1.57 |
Enterprise Value 20434555094 | Price to Sales(TTM) 1.57 | ||
Enterprise Value to Revenue 2.46 | Enterprise Value to EBITDA 15.83 | Shares Outstanding 173012992 | Shares Floating 138339402 |
Shares Outstanding 173012992 | Shares Floating 138339402 | ||
Percent Insiders 20 | Percent Institutions 67.82 |
Analyst Ratings
Rating 3.25 | Target Price 82.17 | Buy 2 | Strong Buy 1 |
Buy 2 | Strong Buy 1 | ||
Hold 8 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Solventum Corp.
Company Overview
History and Background
Solventum Corp. was spun off from 3M in April 2024. While details about its long-term history as an independent entity are still developing, it inherits a strong legacy of innovation and expertise from its parent company, 3M, particularly in healthcare-related products and solutions.
Core Business Areas
- Medical Solutions: Wound care, skin care, and infection prevention products used in hospitals and clinics.
- Health Information Systems: Software and services that help healthcare providers manage patient data and improve outcomes.
- Oral Care Solutions: Dental and orthodontic products and supplies.
- Purification and Filtration: Filtration products used in water treatment and industrial applications.
Leadership and Structure
Details are emerging as the company transitions into a standalone entity, however, Bryan Hanson is the CEO. The organizational structure is likely designed to support focused operations across its core business segments.
Top Products and Market Share
Key Offerings
- Wound Care Products: Advanced wound dressings, tapes, and closures. Market share varies by product category; major competitors include Smith & Nephew, ConvaTec, and Molnlycke Health Care.
- Dental Adhesives & Restoratives: Dental adhesives, restoratives, and cements used by dental professionals. Competitors include Dentsply Sirona and Ivoclar Vivadent.
- Health Information Systems: Software platform and related services that allow providers to manage medical data and patient health. A competitor is Cerner/Oracle Health.
Market Dynamics
Industry Overview
The healthcare and industrial solutions markets are experiencing growth due to aging populations, increased healthcare spending, and demand for advanced technologies.
Positioning
Solventum is positioned as a leading provider of innovative healthcare and industrial solutions, leveraging its heritage and expertise from 3M. Its competitive advantages include a strong brand reputation and extensive distribution network.
Total Addressable Market (TAM)
The TAM across Solventum's segments is estimated to be several hundred billion dollars globally. Solventum is poised to capture a portion of this TAM by focusing on key growth areas and innovation.
Upturn SWOT Analysis
Strengths
- Strong brand recognition inherited from 3M
- Established distribution network
- Diversified product portfolio
- Expertise in healthcare and industrial markets
- Innovation capabilities
Weaknesses
- Newly independent company, need to establish independent identity
- Potential for integration challenges related to separation from 3M
- Reliance on existing patents and intellectual property
- Limited financial data as an independent company
Opportunities
- Expand into new geographic markets
- Develop innovative products and solutions to address unmet needs
- Acquire complementary businesses
- Strengthen partnerships with healthcare providers and distributors
Threats
- Increased competition from established players and emerging companies
- Economic downturn affecting healthcare spending
- Regulatory changes impacting healthcare and industrial markets
- Disruptive technologies impacting existing product lines
Competitors and Market Share
Key Competitors
- JNJ
- BSX
- DHR
- SYK
- MEDP
Competitive Landscape
Solventum faces competition from larger, more established players in the healthcare and industrial markets. It can differentiate itself through innovation, product quality, and customer service.
Growth Trajectory and Initiatives
Historical Growth: Growth trends can be inferred from the historical performance of the spun-off divisions within 3M.
Future Projections: Analyst estimates will be developed as Solventum establishes its track record as an independent company.
Recent Initiatives: Focus on innovation, product development, and geographic expansion.
Summary
Solventum is a new but promising entity spun off from 3M, inheriting a strong foundation and a diverse portfolio. While it faces challenges in establishing itself as an independent company and navigating competition, its focus on innovation and growth could lead to significant opportunities. The company's success will depend on effective execution of its strategic initiatives and adapting to the evolving market dynamics.
Peer Comparison
Sources and Disclaimers
Data Sources:
- 3M Investor Relations
- Solventum Investor Relations
- Market research reports
- Analyst reports
- SEC Filings
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market conditions and company performance can change rapidly, and past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Solventum Corp.
Exchange NYSE | Headquaters Maplewood, MN, United States | ||
IPO Launch date 2024-03-26 | CEO & Director Mr. Bryan C. Hanson | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 22000 | Website https://www.solventum.com |
Full time employees 22000 | Website https://www.solventum.com |
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates in four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment offers solutions for negative pressure wound therapy, advanced wound dressings, advanced skin care, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wrap, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. Its Dental Solutions segment provides a suite of dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions and services for health care systems, such as computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. Its Purification and Filtration segment provides purification and filtration technologies comprising filters, purifiers, cartridges, and membranes. The company sells its products and services through direct-to-consumer, distribution, key account management, inside sales, and e-commerce. Solventum Corporation was incorporated in 2023 and is based in Maplewood, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.